



# Quarterly Camelid TB Serology Report for 2026 - Qtr 1

## Number of Samples Tested and Submission Reason 2026 - Qtr 1

**Table 1a**

Country	No. Samples Tested
England	174
Non GB	0
Not Known	0
Scotland	0
Wales	43
<b>Total</b>	<b>217</b>

**Table 1b**

Project Group	No. Samples Tested
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>1</b>
SER-DIAG	0
SER-EXP	0
SER-MVT	1
SER-RHT	0
<input type="checkbox"/> <b>Other</b>	<b>37</b>
	0
PME	0
SER-SUS	37
TB_DIAG	0
TB_REACT	0
<input type="checkbox"/> <b>Parallel</b>	<b>39</b>
PAR-COL-W	5
PAR-TB	34
PAR-TRC	0
<input type="checkbox"/> <b>Serial</b>	<b>140</b>
SER-CHK	0
SER-COL	47
SER-CONT	93
SER-EPI	0
<b>Total</b>	<b>217</b>

Year, Quarter

2026 (Year) + Qtr 1 (Qua... ▾)

# Quarterly Camelid TB Serology Report for 2026 YTD

## Number of Samples Tested and Submission Reason 2026 to the end of Qtr 1

**Table 2a**

Country	No. Samples Tested
England	174
Non GB	0
Not Known	0
Scotland	0
Wales	43
<b>Total</b>	<b>217</b>

**Table 2b**

Project Group	No. Samples Tested
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>1</b>
SER-DIAG	0
SER-EXP	0
SER-MVT	1
SER-RHT	0
<input type="checkbox"/> <b>Other</b>	<b>37</b>
	0
PME	0
SER-SUS	37
TB_DIAG	0
TB_REACT	0
<input type="checkbox"/> <b>Parallel</b>	<b>39</b>
PAR-COL-W	5
PAR-TB	34
PAR-TRC	0
<input type="checkbox"/> <b>Serial</b>	<b>140</b>
SER-CHK	0
SER-COL	47
SER-CONT	93
SER-EPI	0
<b>Total</b>	<b>217</b>

Year, Quarter

Multiple selections

# Quarterly Camelid TB Serology Report for 2026 - Qtr 1

Year, Quarter

2026 (Year) + Qtr 1 (Qua... ▾)

## Test Positivity in 2026 - Qtr 1

Table 3

Country	No. Submissions	No. Samples Tested	No. Positive Samples	% Positive Samples
<input type="checkbox"/> <b>England</b>	<b>15</b>	<b>174</b>	<b>8</b>	<b>4.6 %</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0.0 %</b>
SER-DIAG	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	1	1	0	0.0 %
SER-RHT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>2</b>	<b>37</b>	<b>1</b>	<b>2.7 %</b>
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	2	37	1	2.7 %
TB_DIAG	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>1</b>	<b>34</b>	<b>7</b>	<b>20.6 %</b>
PAR-TB	1	34	7	20.6 %
PAR-TRC	0	0	0	NaN
<input type="checkbox"/> <b>Serial</b>	<b>11</b>	<b>102</b>	<b>0</b>	<b>0.0 %</b>
SER-CHK	0	0	0	NaN
SER-COL	2	47	0	0.0 %
SER-CONT	9	55	0	0.0 %
SER-EPI	0	0	0	NaN
<input type="checkbox"/> <b>Non GB</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
<input type="checkbox"/> <b>Not Known</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
SER-MVT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
PAR-TB	0	0	0	NaN
<input type="checkbox"/> <b>Scotland</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
SER-EXP	0	0	0	NaN
SER-MVT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Wales</b>	<b>6</b>	<b>43</b>	<b>2</b>	<b>4.7 %</b>
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>2</b>	<b>5</b>	<b>1</b>	<b>20.0 %</b>
PAR-COL-W	2	5	1	20.0 %
PAR-TB	0	0	0	NaN
<input type="checkbox"/> <b>Serial</b>	<b>4</b>	<b>38</b>	<b>1</b>	<b>2.6 %</b>
SER-COL	0	0	0	NaN
SER-CONT	4	38	1	2.6 %
SER-EPI	0	0	0	NaN
<b>Total</b>	<b>21</b>	<b>217</b>	<b>10</b>	<b>4.6 %</b>

# Quarterly Camelid TB Serology Report for 2026 YTD

## Test Positivity in 2026 to the end of Qtr 1

Table 3

Country	No. Submissions	No. Samples Tested	No. Positive Samples	% Positive Samples
<input type="checkbox"/> <b>England</b>	<b>15</b>	<b>174</b>	<b>8</b>	<b>4.6 %</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0.0 %</b>
SER-DIAG	0	0	0	NaN
SER-EXP	0	0	0	NaN
SER-MVT	1	1	0	0.0 %
SER-RHT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>2</b>	<b>37</b>	<b>1</b>	<b>2.7 %</b>
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	2	37	1	2.7 %
TB_DIAG	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>1</b>	<b>34</b>	<b>7</b>	<b>20.6 %</b>
PAR-TB	1	34	7	20.6 %
PAR-TRC	0	0	0	NaN
<input type="checkbox"/> <b>Serial</b>	<b>11</b>	<b>102</b>	<b>0</b>	<b>0.0 %</b>
SER-CHK	0	0	0	NaN
SER-COL	2	47	0	0.0 %
SER-CONT	9	55	0	0.0 %
SER-EPI	0	0	0	NaN
<input type="checkbox"/> <b>Non GB</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
<input type="checkbox"/> <b>Not Known</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
SER-MVT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
PAR-TB	0	0	0	NaN
<input type="checkbox"/> <b>Scotland</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
<input type="checkbox"/> <b>Commercial/Private Testing</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
SER-EXP	0	0	0	NaN
SER-MVT	0	0	0	NaN
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Wales</b>	<b>6</b>	<b>43</b>	<b>2</b>	<b>4.7 %</b>
<input type="checkbox"/> <b>Other</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>NaN</b>
	0	0	0	NaN
PME	0	0	0	NaN
SER-SUS	0	0	0	NaN
TB_REACT	0	0	0	NaN
<input type="checkbox"/> <b>Parallel</b>	<b>2</b>	<b>5</b>	<b>1</b>	<b>20.0 %</b>
PAR-COL-W	2	5	1	20.0 %
PAR-TB	0	0	0	NaN
<input type="checkbox"/> <b>Serial</b>	<b>4</b>	<b>38</b>	<b>1</b>	<b>2.6 %</b>
SER-COL	0	0	0	NaN
SER-CONT	4	38	1	2.6 %
SER-EPI	0	0	0	NaN
<b>Total</b>	<b>21</b>	<b>217</b>	<b>10</b>	<b>4.6 %</b>

Year, Quarter

Multiple selections



# Quarterly Camelid TB Serology Report for 2026 - Qtr 1

Year, Quarter

Multiple selections ▼

## Table 5: Number of samples Tested by Test Code

Numbers not reflective of total number of samples tested due to test being used in combination

Year ANALYSIS	2026	
	Qtr 1	Total
<b>TC0503</b>		
Camelid TB Enferplex - 2 Spot	34	<b>34</b>
<b>TC0603</b>		
Camelid TB Enferplex - 4 Spot	86	<b>86</b>
<b>TC0611</b>		
Chembio DPP VetTB lateral flow rapid antibody test	60	<b>60</b>
<b>TC0867</b>		
Camelid TB Antibody ELISA	94	<b>94</b>

## Test Criteria

### Submission Reason & Explanation

**APHA /DEFRA:** At Government expense

#### Parallel Test:

**PAR-TB TB:** breakdown herd with confirmed M. bovis infection (including Wales where Officially TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)

**PAR-TRC:** Forward tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in Wales only co-located on the same premises with infected cattle, sheep, deer, goats & pigs)

**PAR-COL-W:** Wales only - camelids under restriction due to sharing a holding (colocation) with an OTFW cattle herd or with other non-bovine animals affected by a culture-confirmed incident

#### Serial Test:

**SER-SUS:** (replaces PAR-SUS) TB strongly suspected but not currently confirmed by laboratory culture – herd under restrictions. If infection is confirmed the initial High Specificity (serial) test results can be reinterpreted at High Sensitivity on request from the APHA case vet.

**SER-CONT:** Herd not under restriction but contiguous to a TB-infected herd

**SER-COL:** Herd not under restriction but co-located with an infected herd of cattle, deer, goats etc. (Eng & Scot only)

**SER-EPI:** Herd not under restriction but TB tested due to an epidemiological link with a known infected herd (e.g. back-tracing)

**SER-CHK:** Inconclusive Reactor check test – e.g. where private Enferplex test has produced a 2-spot-positive result on 2 consecutive occasions

**Commercial/Private:** At Owner expense

**SER-MVT:** Pre- or post-movement test

**SER-EXP:** Pre-export test

The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test performance;

**Table 1 – High Sensitivity / Parallel test options:**

	<b>% Se</b>	<b>95% C.I.</b>	<b>% Sp</b>	<b>95% C.I.</b>
<b>IDEXX /DPP VetTB</b>	74	65.4-82.6	96	93.8-98.2
<b>ENFER 2-SPOT/DPP VetTB</b>	71	62.1-79.9	96.7	95.8-99.4
<b>IDEXX/ENFER 2-SPOT</b>	75	66.5-83.5	97.3	95.4-99.1

Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.

**Table 2 – High Specificity / Serial test options:**

	<b>% Se</b>	<b>95% C.I.</b>	<b>% Sp</b>	<b>95% C.I.</b>
<b>ENFER 4-SPOT</b>	60	50.4-69.9	99.66	98.9-100
<b>IDEXX/DPP VetTB</b>	56	46.3-65.7	100	

Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.

Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko, K., Lawrence, J., Clarke, J., de la Rúa-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and antibody tuberculosis tests in alpacas. *Clin Vaccine Immunol* 19, 1677-1683.